HIGHLIGHTS
Circadian regulator BMAL1 rewires metabolism in a chronic insulin-treated TNBC model Pyruvate links BMAL1 to mitochondrial bioenergetics BMAL1 suppresses tumor proliferation and metastasis in hyperinsulinemic obese mice BMAL1 influences tumor microenvironment in highfat-diet-fed mice
INTRODUCTION
Rhythmic oscillations in cellular activity are coordinated by genes that comprise the core circadian machinery (Bell-Pedersen et al., 2005) . The notion that circadian rhythm disruptions lead to an increased likelihood of mammary tumor development is supported by studies that female workers taking frequent night shifts have disrupted internal clocks and an increased risk of developing breast cancer (BC) (Davis et al., 2001; Schernhammer et al., 2001; Wegrzyn et al., 2017) . It has been reported that circadian genes have anti-tumor roles in multiple cancer types (de Assis et al., 2018; Papagiannakopoulos et al., 2016; Tang et al., 2017) and may act as tumor suppressors by regulating a wide variety of pathophysiological events, including cellular metabolism and pathogenesis of cancer (Cederroth et al., 2019; Lesicka et al., 2018; Lin and Farkas, 2018) . Indeed, disrupted circadian rhythm likely affects multiple hallmarks of cancer, including proliferative signaling maintenance, cell death resistance, replicative immortality, invasion and metastasis activation, and energy metabolism reconfiguration (Hanahan and Weinberg, 2011) .
Epidemiological data also suggest that disrupted circadian rhythm is strongly associated with metabolic syndrome (Verlande and Masri, 2019) . Multiple factors common to metabolic syndrome and its related disorders have been shown to promote BC tumor growth and progression (Hursting et al., 2012) . For example, hyperinsulinemia, or elevated circulating insulin levels, is a hallmark of obesity and pre-diabetes and is associated with higher BC incidence and poor prognosis (Del Giudice et al., 1998; Goodwin et al., 2002; Gunter et al., 2009; Lawlor et al., 2004; Lipscombe et al., 2006; Tsujimoto et al., 2017) . Moreover, multiple reports indicate that metabolic diseases differentially impact individual subtypes of BC (Capasso et al., 2014; Garcia-Estevez and Moreno-Bueno, 2019; Yang et al., 2011) . Overall, despite current studies demonstrating a close relationship among circadian disruption, metabolic syndrome, and cancer progression, the mechanisms linking these together are not yet systematically established. et al., 2005) . Therefore, BMAL1 is an essential clock gene affecting all rhythmic behaviors as the loss of BMAL1 ensures that the circadian heterodimer is disrupted (Bunger et al., 2000) . A number of reports have documented the crosstalk between BMAL1 function and insulin signaling, mitochondrial function, and lipid metabolism in non-cancer tissues (Breit et al., 2018; Dang et al., 2016; Jacobi et al., 2015; Liu et al., 2016; Luciano et al., 2018; Luo et al., 2019; Marcheva et al., 2010; McGinnis et al., 2017; Zhang et al., 2014) . In addition, BMAL1 transcriptionally activates genes important for its own feedback loop (Sato et al., 2006) as well as many cellular processes, including mitochondrial dynamics, cell cycle regulation, and stress responses (Hatanaka et al., 2010; Jacobi et al., 2015; Rey et al., 2011) . Global and liver-specific knockout of BMAL1 resulted in hyperlipidemia and increased lipoprotein production (Pan et al., 2016) . However, the functional role of BMAL1 in BC cell metabolism and tumor progression remains largely unknown.
Understanding how circadian disruption and metabolic dysregulation influence BC can help elucidate the underlying biological mechanisms, especially in the basal-like (BL)/triple-negative BC (TNBC) subtype for which there is currently no effective therapeutic target. In this study, we developed two independent cell models, in vitro and in vivo, to investigate how the deficiency of intrinsic BMAL1 affects cellular metabolic homeostasis and tumor progression of TNBC. We demonstrate a previously unrecognized effect by tumorintrinsic BMAL1 on shaping the mitochondrial fuel flexibility and anti-tumor landscape. Our observations provide insights into the mechanism underlying BMAL1-mediated TNBC suppression and evidence that BMAL1 downregulation in combination with hyperinsulinemic obesity exacerbates TNBC progression and aggressiveness. We discuss the implications of using BMAL1 as a marker, along with diet management, for cancer prevention and therapeutics.
RESULTS

Developing an In Vitro Cell Model to Investigate BMAL1 Function in TNBC
Circadian rhythms not only vary among different organisms but also can be unique in different tissue organs within the same organism (Yoo et al., 2004) . Investigation across cancers originated from different tissues suggested that altered expression of clock genes often shows cancer type-specific pattern and is associated with oncogenic pathways, clinical outcomes, and molecular subtypes (Ye et al., 2018) . To examine the expression profile of canonical core circadian genes across different cancer types, we investigated The Cancer Genome Atlas (TCGA) Pan-Cancer datasets. Consistent with the corroborated link between circadian disruption and BC (Blakeman et al., 2016) , the expression of ARNTL/BMAL1 was significantly down-regulated in primary tumor samples compared with normal tissues in multiple cancer types, including BC ( Figure S1A ). As BC is highly heterogeneous and can be classified into different molecular subtypes (Perou et al., 2000) , subsequent analysis using unsupervised hierarchical clustering revealed that the BL subtype has a distinct circadian gene expression profile among the PAM50 molecular subtypes ( Figure 1A ). Most tumors of BL subtype do not express receptors for estrogen, progesterone, and HER2, the major characteristics of TNBC. This subtype is more aggressive and has a poorer prognosis than other BC subtypes (Subik et al., 2010; Toft and Cryns, 2011) . The average expression of the core circadian genes ( Figure 1B ) and ARNTL/BMAL1 ( Figure 1C ) in the BL and HER2-enriched subtypes was significantly lower compared with the other subtypes. We thereby sought to further study BMAL1 deficiency with the focus on BL/TNBC because circadian rhythm disruption may affect BC in a subtype-dependent manner.
To identify a suitable in vitro cell model, we evaluated a panel of 51 BC cell lines. The gene expression profiles are in general agreement with our observations from the TCGA clinical samples, confirming that circadian gene expression levels differ among the BC subtypes. Among the BL/TNBC cell lines, MDA-MB-231 was selected for its low-to mid-range abundance of circadian gene expression ( Figure S1B ) and ARNTL message ( Figure S1C ). Next, to develop a metabolic phenotype, MDA-MB-231 cells were continuously passaged in media supplemented with insulin for more than 10 passages, referred to as chronic insulin treatment (CIT). To mimic the insulin levels in a post-meal, fed state during pre-diabetes (high insulin with normal glucose), CIT cells treated with 10 or 100 nM insulin were assayed to verify that these cells were no longer sensitive to additional insulin stimulation. As shown in Figure 1D , no strong increase in insulin signaling activation was observed in serum/insulin-deprived (24 h) CIT cells stimulated with a high concentration of insulin at 100 nM, indicating the development of insulin resistance. To examine the effect of CIT on circadian outputs, a serum shock procedure was applied to stimulate and synchronize oscillations of circadian genes (Balsalobre et al., 1998) . Cells grown without insulin exhibited a standard ARNTL mRNA oscillation, whereas we observed decreased amplitude for short-term insulin treatment and an early peak for CIT ( Figure 1E ). Of note, we also tested the same assay with additional cell lines having different abundance of endogenous BMAL1 ( Figure S2A ). Alteration of ARNTL mRNA oscillation was again observed in another TNBC cell line BT549 ( Figure S2B ), as well as progesterone receptor-positive MCF7 cells (Figure S2C) , suggesting that the effect of short-term insulin and CIT on ARNTL mRNA oscillation is common. However, the alteration pattern may vary with different cell types.
The Interplay between BMAL1 and Mitochondrial Adaptations to CIT
The molecular interplay between circadian rhythms and cellular metabolism has been delineated as circadian genes control the nicotinamide adenine dinucleotide (NAD + ) salvage pathway (Nakahata et al., 2009 ). Thus, we conducted oscillating circadian-controlled NAD + assays (Ramsey et al., 2009 ) with untreated and CIT cells.
CIT cells showed a faster peak time and a higher steady-state NAD + /NADH ratio than those in insulin-responsive MDA-MB-231 cells ( Figure S3A ), demonstrating the links among insulin signaling, circadian output, and cellular metabolism. Also, the oxidation of NADH to NAD + links the tricarboxylic acid (TCA) cycle to ATP generation in mitochondria. Based on the above results, we tested the hypothesis that mitochondrial activity may partake in BMAL1 regulation. In r 0 cells (depleted of mitochondrial DNA), we observed a significant decrease in the steady-state BMAL1 protein levels ( Figure S3B ) and mRNA levels of ARNTL/BMAL1, along with its direct target NAMPT, irrespective of CIT ( Figure S3C ). Unlike in MDA-MB-231 cells ( Figure 1E ), there was no detectable difference in ARNTL message oscillation between untreated and CIT r 0 cells ( Figure S3D ). We concluded that the mitochondrial activity is indispensable for the expression and CIT-mediated regulation of BMAL1 and its downstream NAD + -regulating target gene.
Next, we tested the state of mitochondrial respiration in the context of decreased BMAL1 expression. ARNTL-targeting small interfering RNA (siRNA) (siBMAL1) was designed and used to decrease BMAL1 abundance by nearly 90% (Figure 2A ). In both untreated and CIT MDA-MB-231 cells, ARNTLknockdown produced higher levels of intracellular ATP ( Figure 2B ). Moreover, following CIT, BMAL1-knockdown cells produced a higher mitochondria-specific reactive oxygen species signal (reflecting electrons leaking from the electrochemical gradient) compared with control cells ( Figure 2C ). Together, these data suggested that BMAL1 regulates bioenergetic homeostasis and possibly other respiration outputs.
To pinpoint the involvement of BMAL1 in mitochondrial bioenergetics, oxygen consumption rate (OCR) was measured in untreated or CIT MDA-MB-231 cells. In control-knockdown cells, CIT increased OCR in a dose-dependent manner ( Figure S3E ), and an opposite OCR pattern was observed in BMAL1-knockdown cells ( Figure S3F ). BMAL1 knockdown increased basal respiration over control knockdown in untreated cells ( Figure S3G , left panel). Also, BMAL1 was required for CIT to increase maximum respiration, a measurement of respiratory capacity, in a dose-dependent manner ( Figure S3G , right panel). Given the fact that BMAL1 suppresses basal OCR in untreated cells and promotes maximal OCR in CIT cells, BMAL1 conceivably plays a key role in the mitochondrial metabolic adaptation to CIT.
We then investigated how BMAL1-mediated mitochondrial adaptations affect other metabolic parameters by measuring the levels of neutral lipid droplets, a nutrient source for cancer (Petan et al., 2018) . Before assaying, MDA-MB-231 cells were starved of glucose to promote fatty acid mobilization (Rambold et al., 2015) . We observed that BMAL1 knockdown increased the amounts of lipid droplets in both untreated and CIT cells ( Figure S4A ). Also, another functional consequence of CIT and BMAL1knockdown was an increase in the sensitivity to metformin ( Figure S4B ), a biguanide that causes oxidative stress by inhibiting mitochondrial complex I (Mayer et al., 2015) . Last, by measuring extracellular acidification rate, we concluded that neither BMAL1 nor CIT impacted glycolytic activity ( Figures S4C-S4E ) in MDA-MB-231 cells.
Pyruvate Links BMAL1 to Mitochondrial Bioenergetics
Pyruvate is a key link between glycolysis and TCA cycle ( Figure S5A ). Based on the above-mentioned results, we hypothesized that BMAL1 serves a distinct role in regulating pyruvate utilization in untreated and CIT cells. To address this possibility in different BC cells, intracellular pyruvate levels were measured in MDA-MB-231, along with BT549 and MCF7 cells. As we observed in MDA-MB-231 cells (shown in Figure 2A ), CIT did not affect steady-state level of BMAL1 in either BT549 or MCF7 cells ( Figure S5B ). However, CIT increased pyruvate levels in control (without BMAL1 knockdown) MDA-MB-231 ( Figure 2D ) and BT-549 ( Figure S5C ) cells compared with their untreated cells. Also, pyruvate level was not affected by BMAL1 knockdown in untreated MDA-MB-231 cells ( Figure 2D ). In contrast, BMAL1 knockdown in CIT cells decreased pyruvate levels in all three (MDA-MB231, BT549, and MCF7) cell lines ( Figures 2D, S5C , and S5E), suggesting that BMAL1 suppresses pyruvate utilization during CIT adaptation. We then measured OCR in the presence and absence of external pyruvate in MDA-MB-231 cells ( Figure 2E ). As expected, the increased maximal respiration by BMAL1 knockdown depended on external pyruvate availability ( Figure 2F ).
Because BMAL1 is a transcription factor, we posited that BMAL1 regulates genes that metabolize pyruvate (Deng et al., 2018) . We found that BMAL1 knockdown reduced the expression of pyruvate kinase (PKM) and pyruvate carboxylase (PC) (converting phosphoenolpyruvate to pyruvate and converting pyruvate to oxaloacetate, as shown in Figure S5A ) in untreated MDA-MB-231 cells ( Figure 2G ). In comparison, BMAL1 knockdown also markedly decreased PKM, PC, and PDK4 mRNA levels in CIT BT549 ( Figure S5D ), but only showed relatively minor effect in MCF7 cells ( Figure S5F ), suggesting a context-dependent role of BMAL1 in regulating pyruvate metabolism enzyme expression in different BC cells. To test if the effects of BMAL1 on OCR are mediated through its regulation of PKM abundance, we applied PKM-targeting siRNA to lower PKM expression in MDA-MB-231 cells and assayed for mitochondrial respiration activity. Consistently, PKM knockdown increased OCR in untreated cells, but decreased OCR in CIT MDA-MB-231 cells, mimicking the effects seen in BMAL1knockdown ( Figure 2H ). The decreased PC activity could also render pyruvate less available to mitochondria (Perry et al., 2015) . Together, these findings underscored a specific role of BMAL1 in regulating pyruvate metabolism.
To corroborate that BMAL1 affects substrate utilization, specific inhibitors were used to block three major mitochondrial fuels: glutamine, long-chain fatty acids, and pyruvate. Mito Fuel Flex assays demonstrated that BMAL1 knockdown altered substrate capacity, or the ability of cells to increase oxidation of particular fuel to compensate for inhibition of alternative fuels. Specifically, BMAL1knockdown increased glutamine and fatty acid oxidation capacity in both untreated and CIT cells ( Figure 2I , middle and right panels), indicating that BMAL1 suppresses glutamine and fatty acid utilization in MDA-MB-231 cells. However, BMAL1 knockdown increased the capacity of pyruvate oxidation under CIT, but decreased it in the insulin-sensitive cells ( Figure 2I , left panel). Finally, compromised BMAL1 decreased pyruvate ( Figure S6A ), but not glutamine ( Figure S6B ) and fatty acid ( Figure S6C ), dependency in mitochondria of CIT cells. These results demonstrated that BMAL1 regulates substrate usage and that CIT cells require BMAL1 to suppress substrate flexibility. This is consistent with our observations that BMAL1 knockdown mediates reduction of message abundance of key pyruvate metabolism-regulating enzymes ( Figure 2G ). Altogether, we surmised that CIT and BMAL1 counterbalanced the regulation of mitochondrial activity. This observed dual regulation of pyruvate by both BMAL1 and insulin would explain how insulin context alters the effect by BMAL1 on tumor cell metabolism.
BMAL1 Suppresses HFD-Induced Tumor Growth In Vivo
To further establish whether BMAL1 regulates tumor progression in vivo, we used wild-type female C57BL/6 mice coupled with mouse mammary tumor E0771 cells orthotopically implanted in syngeneic lean and obese mice ( Figure S7A ). The advantage of using an allografted syngeneic mouse tumor model over an MDA-MB-231-xenografted NSG mouse model is that C57BL/6 mice are better responsive to highfat diet (HFD) feeding (NSG mice are, but only with litter reduction, Behan et al., 2013) and that we are able to study the interaction between cancer cells and their surrounding tumor microenvironment in an immunocompetent animal model. The E0771 cells were derived from a spontaneously developed TNBC in C57BL/6 mice (Ewens et al., 2005; Yang et al., 2017) . Parental E0771 cells are poorly metastatic when compared with 4T1 cells (Johnstone et al., 2015) and have homozygous mutations in Trp53 and Kras genes (Yang et al., 2011 ) with a detectable BMAL1 expression ( Figure 3A , inset). When mice reached young adulthood at the age of 8 weeks, they were separated into two groups: HFD or low-fat diet (LFD) (Dutta and Sengupta, 2016 ). These two diets had equal calories and sucrose for consistent chow palatability and to ensure consistent caloric intake. HFD comprised 60% fat, whereas LFD had 10%. Fasting insulin and glucose levels were measured before starting the diets and 4 weeks after consuming either HFD or LFD. The results showed that LFD did not cause a notable change in fat mass and fasting insulin levels compared with measurements before starting the diet; however, both increased in HFD-fed mice without affecting fasting glucose levels ( Figure S7B ). To test whether the lack of hyperglycemia in HFD-fed mice is due to hyperinsulinemia, which mimics pre-diabetic state, an oral glucose tolerance test was performed. Following glucose feeding after a starvation period, blood glucose levels spiked faster and remained high longer in HFD-fed mice compared with the mice with LFD ( Figure S7C ). The HFD-fed mice also displayed higher body weight gained than LFD-fed mice, even though food intake did not differ ( Figures S7D and S7E ).
After confirming HFD-induced obesity/hyperinsulinemia, the fourth mammary fat pad on the right side of lean or obese mice was implanted with parental E0771 cells or E0771 cells with stable BMAL1 knockdown. The mice were maintained on their respective diet for an additional 4 weeks. In general, HFD accelerated tumor progression over LFD ( Figure 3A ). Upon tumor harvest, BMAL1-knockdown E0771 tumors were not significantly different in size from parental tumors in lean mice, whereas they were larger than the corresponding tumors of parental cells in hyperinsulinemic mice ( Figure 3B ). The E0771/shBMAL1-derived tumors from HFD-fed mice showed the largest sizes among these four groups ( Figure 3B , right panel). There was no notable difference in Ki67, a marker for cell proliferation, signals between tumors from the parental E0771 cells of LFD-and HFD-fed mice; however, BMAL1 knockdown decreased Ki67 signals in tumors harvested from lean, but not hyperinsulinemic, obese mice ( Figure 3C ). E0771/shBMAL1-derived tumors from LFD-fed mice had the least proliferative potential. We next examined whole lungs from obese and lean tumor-harboring mice as lungs are a common site of metastasis from E0771-derived mammary tumors (Yousefi et al., 2018) . Likewise, the obese tumor-bearing mice harbored more lung tumor nodules than the lean group ( Figure 3D ). In addition, BMAL1knockdown decreased the lung tumor nodules in LFD-fed tumorbearing mice, yet significantly increased it in HFD-fed mice. Altogether, BMAL1 serves a non-canonical role of BMAL1 to suppress tumor progression and/or metastasis under hyperinsulinemic obese context.
Last, primary tumor cells from the orthotopically engrafted E0771 tumors were isolated, cultured, and assessed for mitochondrial respiratory function. It is important to note that, recapitulating findings in MDA-MB-231 cells in vitro, BMAL1 knockdown increased OCR in E0771 cells recovered from tumors of lean mice, whereas BMAL1 knockdown decreased OCR in E0771 cells from hyperinsulinemic obese mice ( Figure 3E ). This observation validates the importance of the combined effect of BMAL1-mediated metabolic adaptation and hyperinsulinemia as a determinant of TNBC progression and aggressiveness. In addition, using two different knockdown approaches in cells from two different species yielded comparable conclusion about the role of BMAL1 on mitochondrial bioenergetics, and these separate approaches likely ruled out potential off-target effect(s) of BMAL1 knockdown.
BMAL1 Influences Tumor Microenvironment in Hyperinsulinemic Obese Mice
To further explore how BMAL1 and HFD-induced obesity interactively regulate tumor progression, we examined how the tumor was influenced by the microenvironment. Infiltration of F4/80 macrophage, a major component of the tumor microenvironment, was assessed by immunohistochemistry (Goswami et al., 2017; Hu et al., 2016; Netea-Maier et al., 2018) . Inside the parental E0771-derived tumors, there were no notable differences in F4/80 signals regardless of diet; however, the E0771/shBMAL1-derived tumors in the hyperinsulinemic obese mice, compared with lean mice, exhibited significantly increased F4/80 signals ( Figure 4A ). Other prominent immune cells featured inside tumors are the CD8 + T cells, which play a protective role and are associated with better cancer prognoses and outcomes (Fu and Jiang, 2018) . Tumors from hyperinsulinemic obese mice exhibited significantly decreased CD8 + T cell signals in the parental tumors than those in the lean mice ( Figure 4B ). Notably, there were no differences in CD8 + T cell recruitment in shBMAL1 tumors regardless of diet ( Figure 4B ).
We further performed Gene Set Enrichment Analysis of human primary breast tumor data from TCGA and found that the oxidative phosphorylation (OxPhos) pathway is significantly upregulated in patient tumors with downregulated ARNTL ( Figure 4C ). Such observation is consistent with our findings of increased OCR during BMAL1 knockdown ( Figures S3E and S3F ). Together with Figure S1C , our previously reported increase in OxPhos gene expression in TNBC and HER2-enriched BCs could be attributed to decreased ARNTL expression. In addition, although the metabolic states were not available, our analyses of two independent public datasets for human BC (Kao et al., 2011; Schmidt et al., 2008) revealed that reduced ARNTL expression is associated with worse distal metastasis-free survival ( Figures 4D and 4E ).
DISCUSSION
Although HFD-induced obesity drives tumor growth through multiple mechanisms (Nunez et al., 2008) , our findings support a new paradigm that reduced expression of ARNTL, a key component of the circadian clock, accelerates TNBC tumor growth and lung metastasis in an HFD-induced hyperinsulinemic obese context. Virtually, circadian clock disruption is detrimental to metabolic homeostasis in all cells. To underscore the importance of BMAL1 in the adaptation to hyperinsulinemia in BC cells, here we report that in two different TNBC cells in two distinct models, in vitro and in vivo, BMAL1 loss (BMAL1 crisis) decreases or increases mitochondrial respiration depending on hyperinsulinemia. In parallel, intrinsic BMAL1 oscillation is suppressed by short-term insulin exposure in a mitochondria-dependent manner in MDA-MB-231 cells. We propose a model in which the reduced BMAL1 expression cooperates with HFD-induced hyperinsulinemic obesity to accelerate TNBC tumor progression and lung metastasis through increased mitochondrial fuel flexibility and reshaped recruitment of macrophages and CD8 + T cells ( Figure 4F ).
Cancer cells exhibit metabolic plasticity, rewiring their metabolism to satisfy the demands of rapid cell proliferation and survival (Ghaffari et al., 2015) . Mitochondria comprise a metabolic hub that is responsible for energy production, and also produce building blocks for cell growth by catabolizing glucose, amino acids, and fatty acids. Although we observed that circadian gene expression and mitochondrial activity appear to be interactive and counter-balanced, the detailed underlying mechanism is still not clear. It is plausible that metabolites from the mitochondria directly affect the transcriptional regulation of circadian genes. In addition, post-translational modifications also play a key role in regulating the expression of circadian genes, such as histone acetylation being required at promoters of BMAL1-CLOCK target genes (DiTacchio et al., 2011) . Here, we introduce a link between circadian signaling and mitochondrial function by showing that BMAL1 transcriptionally regulates PKM expression. It hints that endogenous pyruvate production functions as a linchpin for BMAL1-mediated metabolic adaptations. As such, the combined effect of BMAL1 and hyperinsulinemic obesity on reshaping the tumor microenvironment is conceivably mediated by regulating intracellular pyruvate utilization. Our model on the combined effect of intracellular pyruvate and on promoting tumor progression is supported by reports that pyruvate metabolism is important in maintaining colon cancer stem cell proliferation (Schell et al., 2017) and that PKM2-null mice display increased HFD-induced metabolic stress (Dayton et al., 2016) .
Inflammation plays a key role in hyperinsulinemic obesity and metabolic disease (Chawla et al., 2011; Lumeng and Saltiel, 2011 ). In our model, it appears that cancer cell-intrinsic BMAL1 acts as a critical suppressor In summary, our experimental results showed that BMAL1 suppresses TNBC progression in multiple ways: by maintaining the clock machinery and circadian rhythms, by suppressing hyperinsulinemia-dysregulated mitochondrial activity and pyruvate utilization, and by suppressing pro-inflammatory components of the immune microenvironment in the obese context. The latter roles could be attributed to non-canonical circadian functions of BMAL1. In this context, our results provide a compelling case for BMAL1 expression to be examined in patients with TNBC who also present with hyperinsulinemia in the clinic. TNBC tumors with BMAL1 crisis are predicted to have worse outcomes, especially during obesity/hyperinsulinemia. BMAL1 appears to act as a tumor suppressor in TNBC during obesity/hyperinsulinemia, underscoring the importance of understanding BMAL1-mediated mitochondrial metabolic reprogramming during CIT adaptation, which could be exploited pharmacologically or with diet management for better patient outcomes in the future.
Limitations of the Study
There is ample evidence that the cellular circadian clock regulates more than just cell-intrinsic metabolic processes. Based on consistent observations using two distinct models of TNBC, both in vitro and in vivo, we propose a paradigm that BMAL1 serves as a metabolic switch on hyperinsulinemia-regulated mitochondrial activity to govern TNBC tumor progression. Indeed, there is a need to better link circadian biology to cancer risk. Although our findings provide insights regarding the non-canonical BMAL1 function, additional studies are needed to validate how BMAL1 loss (BMAL1 crisis) influences most cases of BC in different metabolic states and whether these insights can be leveraged into an effective therapy. Also, although we demonstrated that BMAL1 crisis confers advantages to cancer cells in both intrinsic metabolism and extrinsic inflammatory microenvironment during hyperinsulinemia, the underlying signaling mechanism among BMAL1 crisis, hyperinsulinemia, and tumorigenesis in vivo remains to be established.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file.
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We thank the members of Dr. Ann's laboratory and Drs. Rama Natarajan and Lei Jiang for helpful discussions on the manuscript. We thank Dr. as fat mass divided by total mass (upper panels). Mice were fasted for five hours before serum was collected and assayed for insulin levels (middle panels) and glucose levels (lower panels).
Measurements were taken before the controlled diet and after 4 weeks of low-fat diet ( infected media with polybrene (2 µg/ml). Successfully transduced cells were selected by puromycin as described previously ).
Short-term insulin treated cells were first starved with serum-free DMEM for 24 h and incubated with insulin (100 nM)-containing medium for 24 h. To establish cells subjected to chronic insulin treatment (CIT), cells were cultured in growth medium containing human recombinant insulin (100 nM; Thermo Fisher, 12585014) for at least 10 passages. For cell entrainment, cells were grown overnight in serum-free media, then incubated in DMEM with fetal bovine serum (50%) for 2 h using a previously described serum shock procedure (Balsalobre et al., 1998) . The entrained cells were washed with phosphate buffered saline after the serum shock and were grown in serum-free media for the remainder of the experiments.
For culturing cells from excised tumor, tumor mass was minced and digested with 1X collagenase/hyaluronidase (Stem Cell Technologies, 07912) at 37 ºC for 1 h, with pipetting through a 10-ml serological pipet every 15 min. Cell suspension was passed through a 70-µm strainer and red blood cells were lysed with ACK Lysing Buffer (Thermo Fisher, A1049201) for 1 min. After centrifugation, cells in supernatant were cultured in media for E0771 cells.
Western Blot
Cells were seeded at a density of 510 5 cells per well in six well plates. The medium was changed to serum-free medium at 48 h post-seeding. Insulin (100 nM in serum-free medium) 
ATP measurement
For ATP measurement, MDA-MB-231 cells untreated or treated with insulin in 12-well plates.
Cells were lysed in 1% trichloroacetic acid and 0.1% tris-acetate. The lysate was clarified by centrifugation at 16000g for 10 mins at 4C. ATP levels were measured using the luciferasebased ENLITEN ATP Assay System (Promega, FF2000) and detected using the Synergy H1
Microplate Reader (Biotek). Measurements were normalized to cell number.
Quantitative RT-PCR analysis
RNAs were isolated by homogenizing cells with QIAshredder columns (QIAGEN, 79654) and purifying RNA using the Quick-RNA Kit (Zymo, R1054). cDNA was synthesized using the iScript Kit (Bio-Rad, 1708890) and the qRT-PCR reaction utilized the components contained in the iTaq Universal SYBR Green Supermix (Bio-Rad, 1725120). Reaction was performed in the iQ5
Thermal Cycler (Bio-Rad) and data was analyzed by the 2 ∆∆Ct method and normalized to GAPDH. The sequences of primer pairs used are:
ARNTL ( 
NADH and NAD
+ /NADH analysis
Samples were prepared using reagents from the NAD/NADH-Glo Assay Kit (Promega, 9071).
Briefly, the siRNA-transfected MDA-MB-231 cells were seeded in 96-well white opaque plates, and sets of cells underwent serum shock every 4 h so that all time points of NAD + and NADH samples were harvested at the same time. Cells were lysed using solution containing Trizma base, hydrochloric acid, and dodecyltrimethylammonium bromide per the instructions in assay kit. Luminescence was detected using the Synergy H1 Microplate Reader (Biotek).
Genetic knockdown by siRNAs
The siRNAs are pooled sets of three target-specific siRNAs that are 19 to 25 nucleotides long.
siRNAs were used to knock down expression of BMAL1/ARNTL and PKM (Santa Cruz, sc-38165 and sc-62820, respectively). The control siRNA (Santa Cruz, sc-37007) contains a scrambled sequence and served as a negative control. The transfection reaction used Lipofectamine RNAiMAX (Thermo Fisher, 13778150) and the manufacturer-recommended protocol using Opti-MEM I Reduced Serum Medium (Thermo Fisher, 11058021).
Mito Stress Test assay
One day prior to assay, cells were counted and seeded 5x10 4 on assay plate in XF Assay Medium (Agilent, 102365) supplemented with glucose (25 mM) and pyruvate (1 mM) overnight.
During assay, cells were sequentially injected to obtain final concentrations of oligomycin (1 µM), trifluoromethoxy carbonylcyanide phenylhydrazone (0.5 µM, FCCP), and rotenone (2.5 µM)
according to manufacturer's protocol. Oxygen consumption rate (OCR) was measured using the Seahorse Extracellular XFe96 Analyzer (Agilent) and normalized to cell number. Basal respiration is calculated as the OCR measurement prior to oligomycin injection subtracted by the measurement after rotenone injection. Maximum respiration is the OCR measurement after FCCP injection subtracted by the measurement after rotenone injection.
Glycolysis Stress Test assay
Cells were seeded as in OCR assays. During the assay, cells were sequentially injected to obtain final concentrations of glucose (10 mM), oligomycin (1 µM), and 2-deoxyglucose (50 mM)
according to manufacturer's protocol. Extracellular acidification rate was measured using the Seahorse Extracellular XFe96 Analyzer (Agilent) and normalized to cell number. Glycolysis is calculated as the ECAR measurement after glucose injection subtracted by the measurement before glucose injection. Glycolytic reserve is the ECAR measurement after oligomycin injection subtracted by the measurement after glucose injection.
Neutral lipid assay
Cells were harvested by trypsinization, and incubated for 30 mins in the dark with BODIPY 493/503 (5 ng/ml, Thermo Fisher, D3922) solution for dyeing neutral lipids. Fluorescent-labeled lipids were detected using BD Accuri C6 Cytometer. Results are reported as relative fluorescence.
Pyruvate assay
Cells were harvested by scraping and lysed with reagents from Pyruvate Assay Kit (Abcam, ab65342). The probe and enzyme from the kit catalyzed a fluorescent with the pyruvate in the sample, and fluorescence was detected at 535/587 nm using the Synergy H1 Microplate Reader (Biotek). Measurements were normalized to cell number.
Mitochondrial ROS assay
Cells were incubated with MitoSOX (3 µM, Thermo Fisher, M36008) for 10 mins at 37 ºC to stain mitochondria-specific superoxide. After staining, the cells were fixed with 2% paraformaldehyde on ice. Fluorescent-labeled mitochondrial superoxide was detected using BD Accuri C6 Cytometer.
Viability assay
To assess viability of cells, cells were stained with trypan blue dye and counted using a 
Metabolic phenotyping
Body composition analysis, oral glucose tolerance test, fasting insulin, and fasting glucose measurements were performed by the City of Hope Comprehensive Metabolic Phenotyping
Core. Fat mass and weight were measured with an EchoMRI a body composition analyzer. For oral glucose tolerance test, mice were fasted for five hours, orally fed glucose and tail vein blood drawn every hour to measure glucose levels. For fasting blood glucose, mice were fasted for five hours and tail vein blood was drawn to measure glucose levels. For fasting insulin, mice were fasted for five hours and tail vein blood was drawn to measure insulin in an enzyme-linked immunosorbent assay.
Statistical analyses
Data are represented as mean and standard error of mean (Mean ± SEM). Statistical analyses were performed using GraphPad Prism 7.0 software (GraphPad Prism Software Inc., San Diego, CA) and R. Normal distribution was confirmed using Shapiro-Wilk normality test before performing statistical analyses. For normally distributed data, comparison between two means
were assessed by unpaired two-tailed Student's t test and that between three or more groups were evaluated using one-way analysis of variance (ANOVA) followed by Tukey's post hoc test.
In animal studies, paired t test was performed to analyze metabolic measurements of individuals before and after HFD or LFD feeding regimen. Brown-Forsythe test confirmed that the variance in the groups compared were not significantly different. All data followed a normal distribution and have equal variances. A p-value lower than 0.05 was considered statistically significant.
Figures were generated using Adobe Illustrator software (San Jose, CA, USA). Power analysis was performed by Power and Sample Size Calculations program (Dupont and Plummer, 1990) .
In each of the independent sample groups containing at least six mice, there is about a 25% standard deviation between tumor sizes. An effect size of 0.5 between groups with this sample size will detected with over 87% power.
